Valuation: GENFIT

Market Cap 44Cr 49Cr 41Cr 37Cr 69Cr 4.66TCr 70Cr 487.94Cr 193.01Cr 2.44TCr 183.96Cr 180.02Cr 7.72TCr P/E 2026 *
-422x
P/E 2027 * -895x
Enterprise Value 41Cr 46Cr 38Cr 34Cr 64Cr 4.36TCr 65Cr 456.56Cr 180.6Cr 2.28TCr 172.13Cr 168.45Cr 7.23TCr EV / Sales 2026 *
5.16x
EV / Sales 2027 * 3.09x
Free-Float
86.79%
Yield 2026 *
-
Yield 2027 * -
1 day+19.63%
1 week+16.44%
Current month+5.65%
1 month+6.50%
3 months-23.17%
6 months+28.91%
Current year+99.05%
1 week 8.47
Extreme 8.47
10.56
1 month 7.72
Extreme 7.72
10.56
Current year 5.05
Extreme 5.05
15.48
1 year 3.4
Extreme 3.4
15.48
3 years 2.62
Extreme 2.62
15.48
5 years 2.62
Extreme 2.62
15.48
10 years 2.62
Extreme 2.62
35.65
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 58 16/06/2017
Director/Board Member 70 16/06/2017
Date Insider Type Main position Quantity % Market Cap. Importance
05/03/26 Exercice

Chief Operating Officer

11,250 0.0225%
05/03/26 Exercice

Chief Operating Officer

7,083 0.0142%
05/03/26 Sell

Chief Operating Officer

7,083 0.0142%
Change 5-day change 1-year change 3-year change Capi.($)
+19.63%+16.44%+185.87%+247.02% 49Cr
+0.88%-0.34%+40.64%+73.05% 6.53TCr
-0.54%-0.54%+9.20%+76.52% 5.46TCr
-0.79%+0.74%+8.81%+100.13% 5.36TCr
-2.06%+2.90%+24.07%+48.36% 4.5TCr
-1.79%+0.19%+19.32%+123.62% 4.22TCr
-1.65%+0.96%+237.56%+823.66% 3.94TCr
-2.26%-4.14%+15.38%+45.53% 3.27TCr
-2.70%-10.77%+19.80%-6.47% 2.4TCr
+0.03%+13.95%+58.56%+47.73% 2.65TCr
Average +0.88%+2.69%+61.92%+157.91% 3.84TCr
Weighted average by Cap. -0.97%+2.28%+45.63%+148.23%

Financials

2026 *2027 *
Net sales 7.95Cr 8.89Cr 7.35Cr 6.66Cr 12Cr 845.39Cr 13Cr 88Cr 35Cr 442.17Cr 33Cr 33Cr 1.4TCr 13Cr 14Cr 12Cr 11Cr 20Cr 1.36TCr 20Cr 142.23Cr 56Cr 710.95Cr 54Cr 52Cr 2.25TCr
Net income -10.94L -12.23L -10.12L -9L -17.15L -12Cr -17.43L -1.22Cr -48.18L -6.09Cr -45.92L -44.94L -19Cr 48.67L 54.42L 45.03L 40.77L 76.3L 52Cr 77.55L 5.42Cr 2.14Cr 27Cr 2.04Cr 2Cr 86Cr
Net Debt -2.82Cr -3.15Cr -2.61Cr -2.36Cr -4.42Cr -299.88Cr -4.49Cr -31Cr -12Cr -156.85Cr -12Cr -12Cr -496.62Cr -4.37Cr -4.88Cr -4.04Cr -3.66Cr -6.85Cr -464.6Cr -6.96Cr -49Cr -19Cr -243Cr -18Cr -18Cr -769.41Cr
Projected Income Statement - Annual - GENFIT
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
180
Date Price Change Volume
27/26/27 €10.48 +19.63% 5,92,273
26/26/26 €8.760 +1.04% 2,02,679
23/26/23 €8.670 -2.47% 1,67,768
22/26/22 €8.890 -4.10% 4,06,182
21/26/21 €9.270 +3.00% 3,04,234
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - GENFIT
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.760EUR
Average target price
17.48EUR
Spread / Average Target
+99.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GENFIT
  1. Stock Market
  2. Stocks
  3. GNFT Stock